| Customization: | Available |
|---|---|
| Package: | 4*14tablets/Box |
| Composition: | Apixaban |
|
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product | Dose | Package |
| Apixaban Tablets | 2.5mg | 4*14Tablets/box |
Apixaban Tablets belong to a class of medications known as direct oral anticoagulants (DOACs) or non-vitamin K antagonist oral anticoagulants (NOACs). They are used primarily for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) and for the treatment and prevention of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban offers several advantages over traditional anticoagulants, including predictable pharmacokinetics, fewer drug interactions, and no requirement for routine monitoring of coagulation parameters.
Nonvalvular Atrial Fibrillation (NVAF): Apixaban Tablets are indicated for the reduction of stroke and systemic embolism risk in patients with nonvalvular atrial fibrillation (NVAF), a common heart rhythm disorder associated with an increased risk of thromboembolic events.
Venous Thromboembolism (VTE): Additionally, apixaban is used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of recurrent VTE in patients who have completed initial anticoagulant therapy.
Nonvalvular Atrial Fibrillation (NVAF): Apixaban Tablets are indicated for the reduction of stroke and systemic embolism risk in patients with nonvalvular atrial fibrillation (NVAF), a common heart rhythm disorder associated with an increased risk of thromboembolic events.
Venous Thromboembolism (VTE): Additionally, apixaban is used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of recurrent VTE in patients who have completed initial anticoagulant therapy.
Safety and Considerations:
Patients receiving apixaban therapy should be monitored regularly for signs of bleeding, including bruising, petechiae, hematomas, or unexplained bleeding. Dose adjustments may be necessary in patients with renal impairment or other risk factors for bleeding.
Apixaban should be used with caution in patients with a history of gastrointestinal bleeding, intracranial hemorrhage, or other conditions predisposing to increased bleeding risk.
){kind=link}